Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaofang Deng
Observed names:
Deng, Xiaofang,
X Deng,
Xiaofang DENG
Institutions:
Guangzhou Medical University Cancer Hospital,
Guangzhou Medical University
Observed institutions:
Guangxi Medical University,
Wenzhou Medical University,
First Affiliated Hospital of Wenzhou Medical University,
Guangzhou First People's Hospital,
Guangzhou Medical University Cancer Hospital,
Guangzhou Medical University
show all 6
ORCID:
0000-0002-8049-077X
Observed ORCID:
0000-0002-8049-077X
OpenAlex ID:
A5063319561
NEK2 serves as a prognostic biomarker for hepatocellular carcinoma
2017
·
Gang Li
, Yanping Zhong
, et al.
·
International Journal of Oncology
·
65
PDF
Development and validation of a machine learning algorithm–based risk prediction model of pressure injury in the intensive care unit
2022
·
Jie Xu
, Danxiang Chen
, et al.
·
International Wound Journal
·
50
UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer.
2017
·
Jun Yin
, Wei Luo
, et al.
·
PubMed
·
36
The significance of Hashimoto’s thyroiditis for postoperative complications of thyroid surgery: a systematic review and meta-analysis
2021
·
X Gan
, J Feng
, et al.
·
Annals of The Royal College of Surgeons of England
·
29
Transcriptomic and Proteomic Investigation of HSP90A as a Potential Biomarker for HCC
2015
·
Yi Zhou
, Xiaofang Deng
, et al.
·
Medical Science Monitor
·
26
PDF
Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study
2020
·
Kun Chen
, Xiaofang Deng
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
18
Cellular transcriptomics: gelsolin negatively regulates the expression of apoptosis-associated genes and inhibits apoptosis in hepatocarcinoma cells.
2015
·
Yi Zhou
, Xiaofang Deng
, et al.
·
PubMed
·
11
Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study
2020
·
Kun Chen
, Xiaofang Deng
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
10
p75NTR promotes survival of breast cancer resistant cells by regulating Bcl-2/Bax and MAPK pathway.
2017
·
Xiaofang Deng
, Gang Xu
, et al.
·
PubMed
·
9
[Establishment of metastatic sub-clone from estrogen independent Ishikawa cells and its characterization in vitro and in vivo].
1995
·
H Sakamoto
, X Deng
, et al.
·
PubMed
·
7
Mining the Prognostic Role of DNA Methylation Heterogeneity in Lung Adenocarcinoma
2022
·
Hongying Liao
, Xiaolong Luo
, et al.
·
Disease Markers
·
3
PDF
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
·
Blood Cancer Discovery
·
2
[Differentiated microcarcinoma of the thyroid gland in 45 cases].
2001
·
J Wang
, X Qiu
, et al.
·
PubMed
·
2
MicroRNA-920 enhances chemosensitivity in esophageal squamous cell carcinoma by targeting YAP
2021
·
Xiaofang DENG
, Zhong HUANG
, et al.
·
Minerva Medica
·
1
Table S4 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Supplementary Protocol 1 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Figure S1 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S7 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S1 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S3 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S6 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Data from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S2 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Table S5 from Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
2026
·
Ruixian Xing
, Apeng Yang
, et al.
Development and Validation a Nomogram and Prognosis of Chemotherapy for Evaluation in Giant-cell Lung Carcinoma With Metastases: A Propensity Score Matching Analysis
2020
·
Zhihao Yang
, Kun Chen
, et al.
PDF
Show more works
View as search
Works count:
28
Citation count:
269
H-index:
9
I10-index:
8
Year
Topic
Type